Tsubota Laboratory announced the submission of the final clinical trial report for the myopia progression suppression device “TLG-001” and achievement of a milestone. In the fiscal year ending March 2027, a one-time payment is scheduled to be recognized as sales, with safety confirmed.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4890","jir_company_name":"Tsubota Laboratory, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-22","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4890-20260722-01.pdf","jir_short_summary":"Tsubota Laboratory announced the submission of the final clinical trial report for the myopia progression suppression device \"TLG-001\" and achievement of a milestone. In the fiscal year ending March 2027, a one-time payment is scheduled to be recognized as sales, with safety confirmed.","jir_summary":"### Performance Overview\nTsubota Laboratory announced that it submitted the final report for the domestic clinical trial of \"TLG-001,\" a violet light irradiation device aimed at suppressing myopia progression, to its joint development partner, thereby achieving a milestone. Consequently, the company plans to recognize a one-time payment as sales in the fiscal year ending March 2027. The trial results confirmed safety and provided meaningful insights into the relationship between outdoor activity time and myopia progression. Moving forward, preparations are underway for additional trials in China, with the aim of global expansion.\n\n### Future Outlook and Strategy\nThe company is conducting additional trials in China, planning clinical studies targeting children and adolescents with high myopia rates. To maximize product value and obtain approval in the Chinese market, it will collaborate with partner companies to advance business development. Specific schedules and disclosure matters will be announced as appropriate, with a focus on accelerating R&D efforts to realize a society where children are protected from myopia.","jir_financial_highlights":"Scheduled recognition of milestone-based one-time payment as sales: Unknown (Unknown)","jir_category":"","jir_hashtags":"#TsubotaLaboratory, #IR, #JapaneseStocks","jir_key_figures":"Scheduled recognition of milestone-based one-time payment as sales (Unknown)\nExploratory analysis results on outdoor activity time and myopia progression (Specific figures unknown)\nOngoing preparations for additional trials in China (Specific schedule unknown)","jir_meta_title":"\u3010Tsubota Laboratory\u3011 Achievement of Clinical Trial Milestone for Myopia Suppression Device | July 2026","jir_meta_description":"Tsubota Laboratory submitted the final clinical trial report for its myopia progression suppression device, achieving a milestone. A one-time payment is scheduled to be recognized as sales in the fiscal year ending March 2027, with safety confirmed.","jir_og_title":"\u3010Tsubota Laboratory\u3011 Achievement of Milestone in Clinical Trial of Myopia Suppression Device | July 2026","jir_og_description":"Tsubota Laboratory submitted the final clinical trial report for its myopia progression suppression device, with sales recognition planned. Safety has also been confirmed, and further development is anticipated.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":0,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-86510","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n